2023
Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not?
Petrillo A, Maron S, Sundar R. Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not? ESMO Open 2023, 8: 101211. PMID: 37054477, PMCID: PMC10123152, DOI: 10.1016/j.esmoop.2023.101211.Commentaries, Editorials and Letters
2022
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Tay R, Yeong J, Lum J, Teo C, Tan B, Chan Y, Choo J, Jeyasekhran A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Journal Of Clinical Oncology 2022, 40: 4026-4026. DOI: 10.1200/jco.2022.40.16_suppl.4026.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyPD-L1 CPSTumor proportion scorePD-L1Gastric cancerTissue microarrayImmune cellsPatients treated with ICI therapyPD-L1 expression statusPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentGastric cancer immunotherapyPD-L1 scoringPD-L1 immunohistochemistryPD-L1 positivityDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceNational University HospitalWhole slide analysisCut-off